A glucose metabolism advantage drives NSUN2 upregulation in tumor cells, which stabilizes key glycolytic gene transcripts (GLUT1, HK2, PFKM) via mRNA methylation, enhancing tumor cells’ competitive advantage in glucose uptake (75). The gene discussed is SLC2A1; the disease is neoplasm.